Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XOMA Royalty Corporation's filings document the capital structure and public-company reporting for its common stock, 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP), and depositary shares representing interests in its Series B preferred stock on Nasdaq. Recent 8-K disclosures address financial results, Regulation FD materials, material definitive agreements and the completed acquisition of Generation Bio, including supplemental information about legacy assets.
Proxy materials describe annual meeting proposals, shareholder voting procedures and governance matters. For the preferred security, the filing record identifies the registered preferred-stock class and places capital-structure and transaction disclosures in the context of XOMA Royalty's biotechnology royalty aggregation business.
XOMA Royalty Corp’s Chief Investment Officer Bradley Sitko reported equity holdings and a compensation-related share conversion. On the reported date, he exercised 3,737 Performance Stock Units (PSUs) at $0.00 per unit into 3,737 shares of common stock, increasing his directly held common stock to 82,961 shares. The filing shows he continues to hold 41,112 PSUs, which each represent a right to one share of common stock and vest only if the stock reaches specified price levels and he remains in service through each vesting date. The report also lists additional indirect holdings in common stock, preferred stock, and depositary shares held by his spouse, children, and a 401(k) plan.
XOMA Royalty Corp’s Chief Investment Officer Bradley Sitko reported equity holdings and a compensation-related share conversion. On the reported date, he exercised 3,737 Performance Stock Units (PSUs) at $0.00 per unit into 3,737 shares of common stock, increasing his directly held common stock to 82,961 shares. The filing shows he continues to hold 41,112 PSUs, which each represent a right to one share of common stock and vest only if the stock reaches specified price levels and he remains in service through each vesting date. The report also lists additional indirect holdings in common stock, preferred stock, and depositary shares held by his spouse, children, and a 401(k) plan.
XOMA Royalty Corp’s Chief Financial Officer Jeffrey Trigilio exercised 4,000 Performance Stock Units, converting them into 4,000 shares of common stock at an exercise price of $0.00 per share. Each PSU represents a contingent right to receive one share of common stock upon meeting specified stock price and service conditions.
To cover tax obligations related to this vesting, 1,632 common shares were disposed of at $36.76 per share through a tax-withholding transaction, which is not an open-market sale. After these transactions, Trigilio directly holds 92,368 shares of XOMA common stock and 26,000 Performance Stock Units.
XOMA Royalty Corp’s Chief Financial Officer Jeffrey Trigilio exercised 4,000 Performance Stock Units, converting them into 4,000 shares of common stock at an exercise price of $0.00 per share. Each PSU represents a contingent right to receive one share of common stock upon meeting specified stock price and service conditions.
To cover tax obligations related to this vesting, 1,632 common shares were disposed of at $36.76 per share through a tax-withholding transaction, which is not an open-market sale. After these transactions, Trigilio directly holds 92,368 shares of XOMA common stock and 26,000 Performance Stock Units.
XOMA Royalty Corp director Joseph M. Limber exercised stock options to acquire 3,026 shares of common stock at $11.20 per share. The options, which had been fully vested and exercisable since July 21, 2017, were fully exercised, leaving no remaining options from this grant. Following the exercise, he directly holds 9,234 shares of common stock, 20,000 depositary shares of 8.375% Series B cumulative stock, and 10,000 shares of 8.625% Series A cumulative perpetual preferred stock.
XOMA Royalty Corp director Joseph M. Limber exercised stock options to acquire 3,026 shares of common stock at $11.20 per share. The options, which had been fully vested and exercisable since July 21, 2017, were fully exercised, leaving no remaining options from this grant. Following the exercise, he directly holds 9,234 shares of common stock, 20,000 depositary shares of 8.375% Series B cumulative stock, and 10,000 shares of 8.625% Series A cumulative perpetual preferred stock.
XOMA Royalty Corporation has called a virtual annual stockholder meeting for May 21, 2026, and is asking investors to vote on board elections, auditor ratification, equity plans and executive pay. Seven directors, including CEO Owen Hughes and independent chair Jack L. Wyszomierski, are nominated for one-year terms.
Stockholders are asked to ratify Deloitte & Touche as 2026 auditor, approve a 425,000-share increase to the 2010 Long Term Incentive and Stock Award Plan (about 2.5% dilution including 5,003,000 Series X convertible shares), adopt a new 2026 Employee Stock Purchase Plan for 500,000 shares, and give a non-binding say-on-pay vote on executive compensation.
XOMA Royalty Corporation has called a virtual annual stockholder meeting for May 21, 2026, and is asking investors to vote on board elections, auditor ratification, equity plans and executive pay. Seven directors, including CEO Owen Hughes and independent chair Jack L. Wyszomierski, are nominated for one-year terms.
Stockholders are asked to ratify Deloitte & Touche as 2026 auditor, approve a 425,000-share increase to the 2010 Long Term Incentive and Stock Award Plan (about 2.5% dilution including 5,003,000 Series X convertible shares), adopt a new 2026 Employee Stock Purchase Plan for 500,000 shares, and give a non-binding say-on-pay vote on executive compensation.
XOMA Royalty Corp amendment: The Vanguard Group filed a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that led to disaggregated reporting by Vanguard subsidiaries.
The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The filing lists Vanguard's Malvern address and XOMA's principal office at 2200 Powell St, Emeryville, CA.
XOMA Royalty Corp amendment: The Vanguard Group filed a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that led to disaggregated reporting by Vanguard subsidiaries.
The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The filing lists Vanguard's Malvern address and XOMA's principal office at 2200 Powell St, Emeryville, CA.
XOMA Royalty Corp director Jack L. Wyszomierski exercised stock options and increased his direct common share holdings. On March 24, 2026, he exercised a Stock Option for 3,026 shares at $11.20 per share, receiving the same number of Common Stock shares. Following the transaction, he directly owns 21,530 shares of XOMA Royalty Corp common stock. The option had been fully vested and exercisable since July 21, 2017, indicating a routine derivative exercise rather than an open-market purchase or sale.
XOMA Royalty Corp director Jack L. Wyszomierski exercised stock options and increased his direct common share holdings. On March 24, 2026, he exercised a Stock Option for 3,026 shares at $11.20 per share, receiving the same number of Common Stock shares. Following the transaction, he directly owns 21,530 shares of XOMA Royalty Corp common stock. The option had been fully vested and exercisable since July 21, 2017, indicating a routine derivative exercise rather than an open-market purchase or sale.
XOMA Royalty Corporation reports on its 2025 performance as a diversified biotech royalty aggregator. The company now holds economic interests in over 120 assets, including seven commercial products and 14 late-stage programs, and focuses on non-dilutive funding of drug developers.
In 2025, XOMA received $33.6 million in commercial payments and $16.9 million from milestones and other fees, for total cash receipts of $50.5 million. Key commercial contributors included VABYSMO, OJEMDA, MIPLYFFA and IXINITY. DSUVIA revenue was minimal after Alora discontinued commercial sales and later withdrew the product due to manufacturing constraints.
The company expanded its portfolio through transactions such as the Takeda Revenue Share Agreement, Castle Creek’s D‑Fi royalty financing, and acquisitions of Pulmokine and LAVA, adding rights to multiple late‑stage and partnered programs. It also executed a stock repurchase program, buying 648,708 shares for $16.1 million by year-end, and operated with a lean team of 14 employees.
XOMA Royalty Corporation reports on its 2025 performance as a diversified biotech royalty aggregator. The company now holds economic interests in over 120 assets, including seven commercial products and 14 late-stage programs, and focuses on non-dilutive funding of drug developers.
In 2025, XOMA received $33.6 million in commercial payments and $16.9 million from milestones and other fees, for total cash receipts of $50.5 million. Key commercial contributors included VABYSMO, OJEMDA, MIPLYFFA and IXINITY. DSUVIA revenue was minimal after Alora discontinued commercial sales and later withdrew the product due to manufacturing constraints.
The company expanded its portfolio through transactions such as the Takeda Revenue Share Agreement, Castle Creek’s D‑Fi royalty financing, and acquisitions of Pulmokine and LAVA, adding rights to multiple late‑stage and partnered programs. It also executed a stock repurchase program, buying 648,708 shares for $16.1 million by year-end, and operated with a lean team of 14 employees.
XOMA Royalty Corporation reported a strong turnaround for 2025, with income and revenues rising to $52.1 million from $28.5 million in 2024 and net income improving to $31.7 million from a net loss of $13.8 million.
Cash receipts reached $50.5 million, including $33.6 million in royalties and commercial payments and $16.9 million in milestones and fees, and the company generated positive cash flow from operations. XOMA deployed $25.0 million to acquire additional royalty and milestone assets and repurchased 648,048 common shares for $16.0 million.
At December 31, 2025, XOMA held cash and cash equivalents of $133.7 million, including $50.8 million in restricted cash, against long-term debt of $96.5 million. The portfolio expanded to more than 100 assets, with multiple commercial and late-stage programs supporting growing royalty streams.
XOMA Royalty Corporation reported a strong turnaround for 2025, with income and revenues rising to $52.1 million from $28.5 million in 2024 and net income improving to $31.7 million from a net loss of $13.8 million.
Cash receipts reached $50.5 million, including $33.6 million in royalties and commercial payments and $16.9 million in milestones and fees, and the company generated positive cash flow from operations. XOMA deployed $25.0 million to acquire additional royalty and milestone assets and repurchased 648,048 common shares for $16.0 million.
At December 31, 2025, XOMA held cash and cash equivalents of $133.7 million, including $50.8 million in restricted cash, against long-term debt of $96.5 million. The portfolio expanded to more than 100 assets, with multiple commercial and late-stage programs supporting growing royalty streams.
Hughes Owen reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director and Chief Executive Officer Owen Hughes reported new equity awards. On March 16, 2026, he received 126,813 Performance Stock Units, each representing a contingent right to one share of common stock, which vest only if the stock reaches specified price targets and he remains in service.
He was also granted 82,428 restricted stock units payable solely in common stock. These RSUs vest in four equal 25% installments on each of the first four anniversaries of March 11, 2026, subject to continued service. Following these awards, he holds 180,696 common shares directly, 295 common shares indirectly via a 401(k) plan, and 102,000 depositary shares of 8.375% Series B cumulative stock.
Hughes Owen reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director and Chief Executive Officer Owen Hughes reported new equity awards. On March 16, 2026, he received 126,813 Performance Stock Units, each representing a contingent right to one share of common stock, which vest only if the stock reaches specified price targets and he remains in service.
He was also granted 82,428 restricted stock units payable solely in common stock. These RSUs vest in four equal 25% installments on each of the first four anniversaries of March 11, 2026, subject to continued service. Following these awards, he holds 180,696 common shares directly, 295 common shares indirectly via a 401(k) plan, and 102,000 depositary shares of 8.375% Series B cumulative stock.
XOMA ROYALTY CORPORATION ownership update: FMR LLC reports beneficial ownership of 1,268,506.14 shares of common stock, representing 10.2% of the class as of 02/27/2026. The filing also notes that Fidelity Contrafund held 773,332 shares, or 6.2%, as of the same date.
The schedule is an amendment (No. 5) and identifies filings and powers of attorney authorizing the submission; Exhibit 99 and related exhibits are referenced for subsidiary and agreement details.
XOMA ROYALTY CORPORATION ownership update: FMR LLC reports beneficial ownership of 1,268,506.14 shares of common stock, representing 10.2% of the class as of 02/27/2026. The filing also notes that Fidelity Contrafund held 773,332 shares, or 6.2%, as of the same date.
The schedule is an amendment (No. 5) and identifies filings and powers of attorney authorizing the submission; Exhibit 99 and related exhibits are referenced for subsidiary and agreement details.